Amryt Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Amryt Pharma has a total shareholder equity of $324.3M and total debt of $208.6M, which brings its debt-to-equity ratio to 64.3%. Its total assets and total liabilities are $736.9M and $412.6M respectively.
Key information
64.3%
Debt to equity ratio
US$208.60m
Debt
| Interest coverage ratio | n/a |
| Cash | US$83.25m |
| Equity | US$324.28m |
| Total liabilities | US$412.60m |
| Total assets | US$736.88m |
Recent financial health updates
Recent updates
Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU
Oct 18Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval
Sep 16Amryt gets British marketing approval & orphan drug designation for rare skin disease gel
Sep 08Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition
Jul 14Amryt's Filsuvez gets approval in EU to treat rare skin disorder
Jun 23Amryt Pharma: Advancing Novel Treatments For Rare And Debilitating Conditions
Dec 09Chiasma surges on merger agreement with Amryt
May 05Amryt and Medison Pharma inks distribution deal for Juxtapid, Lojuxta and Myalept
Feb 04Amryt's AP103 an Orphan Drug in U.S. for skin blistering disorder
Dec 23Amryt Group's Lojuxta receives marketing approval in Brazil
Dec 09Financial Position Analysis
Short Term Liabilities: AMYT's short term assets ($224.4M) exceed its short term liabilities ($143.1M).
Long Term Liabilities: AMYT's short term assets ($224.4M) do not cover its long term liabilities ($269.5M).
Debt to Equity History and Analysis
Debt Level: AMYT's net debt to equity ratio (38.7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if AMYT's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable AMYT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: AMYT is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 45.1% per year.